Cargando…

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy elicits durable antitumor responses in patients with many types of cancer. Genomic mutations may be used to predict the clinical benefits of ICI therapy. NOTCH homolog-4 (NOTCH4) is frequently mutated in several cancer types, but its role in immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Long, Junyu, Wang, Dongxu, Yang, Xu, Wang, Anqiang, Lin, Yu, Zheng, Mingjun, Zhang, Haohai, Sang, Xinting, Wang, Hanping, Hu, Ke, Zhao, Haitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293505/ https://www.ncbi.nlm.nih.gov/pubmed/34284787 http://dx.doi.org/10.1186/s12916-021-02031-3

Ejemplares similares

Identification of TMB, CD8 T‐cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit–toxicity ratio of anti‐PD‐1/PD‐L1 therapy
por: Long, Junyu, et al.
Publicado: (2021)

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape
por: Long, Junyu, et al.
Publicado: (2022)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Identification of hub genes involved in the development of hepatocellular carcinoma by transcriptome sequencing
por: Zheng, Yongchang, et al.
Publicado: (2017)

Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
por: Yang, Xu, et al.
Publicado: (2021)

Citrus Fruit Intake Substantially Reduces the Risk of Esophageal Cancer: A Meta-Analysis of Epidemiologic Studies
por: Wang, Anqiang, et al.
Publicado: (2015)

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
por: Long, Junyu, et al.
Publicado: (2019)

Combination treatment including targeted therapy for advanced hepatocellular carcinoma
por: Lin, Jianzhen, et al.
Publicado: (2016)

Coffee and cancer risk: A meta-analysis of prospective observational studies
por: Wang, Anqiang, et al.
Publicado: (2016)

Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma
por: Zhang, Haohai, et al.
Publicado: (2015)

Systematic review and meta-analysis: cholecystectomy and the risk of cholangiocarcinoma
por: Xiong, Jianping, et al.
Publicado: (2017)

Clinicopathological Features of Gallbladder Papillary Adenocarcinoma
por: Wan, Xueshuai, et al.
Publicado: (2014)

Association of chronic liver disease with the prognosis of COVID-19 patients
por: Long, Junyu, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022)

Mutational spectrum and precision oncology for biliary tract carcinoma
por: Lin, Jianzhen, et al.
Publicado: (2021)

Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer
por: Lin, Anqi, et al.
Publicado: (2023)

Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
por: Lin, Jianzhen, et al.
Publicado: (2018)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events
por: Zheng, Ke, et al.
Publicado: (2020)

Gallbladder papillary neoplasms share pathological features with intraductal papillary neoplasm of the bile duct
por: Wan, Xueshuai, et al.
Publicado: (2017)

TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
por: Qiu, Tianzhu, et al.
Publicado: (2022)

Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma
por: Wang, Yunchao, et al.
Publicado: (2022)

EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers
por: Zhang, Zhen, et al.
Publicado: (2021)

Comprehensive analysis of a ceRNA network reveals potential prognostic cytoplasmic lncRNAs involved in HCC progression
por: Bai, Yi, et al.
Publicado: (2019)

Immune checkpoint inhibitor‐related molecular markers predict prognosis in extrahepatic cholangiocarcinoma
por: Jin, Bao, et al.
Publicado: (2023)

Dr.VIS v2.0: an updated database of human disease-related viral integration sites in the era of high-throughput deep sequencing
por: Yang, Xiaobo, et al.
Publicado: (2014)

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC
por: Li, Xiaohua, et al.
Publicado: (2021)

Multi‐cohort analysis identifies somatic NTRK mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma
por: Yan, Junya, et al.
Publicado: (2023)

Clinical characteristics and management of immune checkpoint inhibitor‐related pneumonitis: A single‐institution retrospective study
por: Wang, Hanping, et al.
Publicado: (2020)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
por: Guo, Xiaoxiao, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Wang, Hanping, et al.
Publicado: (2019)

Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Martin, Spencer D., et al.
Publicado: (2023)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections
por: Lu, Minya, et al.
Publicado: (2020)

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
por: Moeckel, Camille, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
por: Valero, Cristina, et al.
Publicado: (2021)

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
por: Pan, Chaohu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1t9ldlghh9att4o8jilfi8utc2